Tuesday, 26 May 2026
  
Login

Australia's most trusted
source of pharma news

Tuesday, 26 May 2026
News

Oncology dethroned as No 1

Posted 26 May 2026 AM

For the first time in Deloitte’s 16 years of analysis, obesity has displaced oncology as the largest contributor to late-stage pipeline value, with the firm warning that this shift could heighten “exposure to therapeutic-area-specific shocks”.

The findings detailed in Deloitte’s latest report, ‘Navigating the GLP-1 boom: Measuring the return from pharmaceutical innovation’ shows obesity assets, almost exclusively driven by GLP-1/GIP candidates, now account for roughly 38 per cent of projected commercial inflows and 25 per cent of forecast sales from 2025 late-stage pipeline

To see the whole article, please login

Popular

Country Leader back after Gap Year
Who's ready for a June PBS listing?
Ninth time a Great Place To Work
Gladys takes health sector role
Latest Jobs
Pharma in Focus  Jobs
MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.


Subscribe
 
© 2003 - 2026 Lush Media | Privacy Statement | Subscribe to Pharma in Focus
home